ライフサイエンスコーパス: hydroxychloroquine

1 us etanercept or MTX plus sulfasalazine plus hydroxychloroquine).

2 r risk was observed among patients receiving hydroxychloroquine.

3 verity and SLE are predictors of response to hydroxychloroquine.

4 ave any significant influence on response to hydroxychloroquine.

5 s (DLE) is the 4-aminoquinolone antimalarial hydroxychloroquine.

6 ficantly associated with lack of response to hydroxychloroquine.

7 study of 200 patients with DLE treated with hydroxychloroquine.

8 hip between disease activity and response to hydroxychloroquine.

9 The primary outcome was clinical response to hydroxychloroquine.

10 sive agents other than low-dose steroids and hydroxychloroquine.

11 herapy, most commonly low-dose prednisone or hydroxychloroquine.

12 .001), compared with those who had not taken hydroxychloroquine.

13 ts were nonadherent to prednisone and 51% to hydroxychloroquine.

14 -0.92) compared with those who had not taken hydroxychloroquine.

15 red suitable for identifying nonadherence to hydroxychloroquine.

16 medications were changed to methotrexate and hydroxychloroquine.

17 reated with prednisone, cyclophosphamide, or hydroxychloroquine.

18 t remained on a regimen of sulfasalazine and hydroxychloroquine.

19 alone or a combination of sulfasalazine, and hydroxychloroquine.

20 Similar results were obtained with hydroxychloroquine.

21 on of sulfasalazine (500 mg twice daily) and hydroxychloroquine (200 mg twice daily), or all three dr

22 eceive minocycline, 100 mg twice per day, or hydroxychloroquine, 200 mg twice per day, in a 2-year, d

23 ; (2) methotrexate without TNF inhibitors or hydroxychloroquine; (3) hydroxychloroquine without TNF i

24 f 35 patients treated with sulfasalazine and hydroxychloroquine (40 percent), P = 0.003 for the compa

25 Patients were randomized (1:1) to receive hydroxychloroquine (400 mg/d) or placebo until week 24.

26 Hydroxychloroquine, 400 mg, or matching placebo once dai

27 pisodes; rate, 23.8; 95% CI, 23.0-24.6); and hydroxychloroquine (50 cases among 5682 treatment episod

28 Hydroxychloroquine, a commonly used antirheumatic medica

29 though the majority of patients responded to hydroxychloroquine, a significant proportion (39%) eithe

30 xate, thiopurines, anti-TNFs, sulfasalazine, hydroxychloroquine, abatacept, or rituximab after the in

31 cells as well as whether the chloroquine or hydroxychloroquine actually inhibit the autophagy.

32 efit, triple therapy, with sulfasalazine and hydroxychloroquine added to methotrexate, was noninferio

33 h such a clot lasts, we investigated whether hydroxychloroquine alters the dynamics of such thrombus

34 ts with rheumatoid arthritis (1808 had taken hydroxychloroquine and 3097 had never taken hydroxychlor

35 es was reported by 54 patients who had taken hydroxychloroquine and by 171 patients who had never tak

36 Mice treated with hydroxychloroquine and IgG-APS showed significantly smal

37 Hydroxychloroquine and low-dose aspirin may have a prote

38 Therapies for RA, especially hydroxychloroquine and methotrexate (MTX) have positive

39 the cohort was controlled by treatment with hydroxychloroquine and nonsteroidal agents.

40 between the 2 groups (-4.8% and -4.2% in the hydroxychloroquine and placebo groups, respectively, at

41 Adherence to 2 medications (hydroxychloroquine and prednisone) was measured in 55 pa

42 studies, there is experimental evidence that hydroxychloroquine and statins may play a role in the ma

43 Hydroxychloroquine and sulfasalazine are compatible with

44 ewly described potential beneficial roles of hydroxychloroquine and the statins for the treatment of

45 hydroxychloroquine and 3097 had never taken hydroxychloroquine) and no diagnosis or treatment for di

46 orioretinopathy, maculopathy associated with hydroxychloroquine, and healthy eyes) were studied.

47 Large trials of glucocorticoid therapy, hydroxychloroquine, and non-steroidal anti-inflammatory

48 ologic conditions, the role of other agents (hydroxychloroquine, antioxidants), and novel immunomodul

49 Finally, an autophagy inhibitor, hydroxychloroquine, approved for use in pregnant women,

50 hy associated with the use of chloroquine or hydroxychloroquine are not undergoing routine monitoring

51 Chloroquine and its analog hydroxychloroquine are the only clinically relevant auto

52 Subjects were identified with hydroxychloroquine as a medication by electronic query a

53 ssociated most strongly with the presence of hydroxychloroquine as defined by mfERG testing.

54 holipid syndrome (IgG-APS) and then fed with hydroxychloroquine at various doses (100, 6, and 3 mg/kg

55 us etanercept or MTX plus sulfasalazine plus hydroxychloroquine) at week 24 if the DAS28-ESR was >/=

56 l involvement in short- and long-term use of hydroxychloroquine before the development of retinopathy

57 All patients were prescribed hydroxychloroquine between weeks 24 and 48.

58 These cases show that high doses of hydroxychloroquine can initiate the development of retin

59 ts with rheumatic diseases, indomethacin and hydroxychloroquine, can directly inhibit HIV-1 replicati

60 for individuals starting a TNF inhibitor or hydroxychloroquine compared with initiation of other non

61 thotrexate, and 0.54 (95% CI, 0.36-0.80) for hydroxychloroquine compared with other nonbiologic DMARD

62 ts with primary Sjogren syndrome, the use of hydroxychloroquine compared with placebo did not improve

63 ot taking antiretroviral therapy, the use of hydroxychloroquine compared with placebo did not reduce

64 ion members among 2361 patients who had used hydroxychloroquine continuously for at least 5 years acc

65 Chloroquine and hydroxychloroquine exert beneficial effects in experimen

66 developed retinal toxic effects after using hydroxychloroquine for a mean of 10.4 years (range, 3-19

67 nts with the pericentral pattern were taking hydroxychloroquine for a somewhat longer duration (19.5

68 ical trial testing high-dose (1000 mg daily) hydroxychloroquine for advanced non-small cell lung canc

69 use, and 1409 (7.8%) had used chloroquine or hydroxychloroquine for at least 4 years.

70 , weight, start date, or dosing; or (3) took hydroxychloroquine for malaria prophylaxis.

71 use (P < .001 for trend); among those taking hydroxychloroquine for more than 4 years (n = 384), the

72 ted steroids, intravenous immunoglobulin and hydroxychloroquine for prevention and treatment of disea

73 phagy stimulator (Tunicamycin) or inhibitor (Hydroxychloroquine) functionally proved that autophagy w

74 less prednisone at 2 years compared with the hydroxychloroquine group (mean 0.81 mg/day compared with

75 ral therapy was started in 9 patients in the hydroxychloroquine group and 1 in the placebo group.

76 e primary end point was 17.9% (10/56) in the hydroxychloroquine group and 17.2% (11/64) in the placeb

77 , there were 2 serious adverse events in the hydroxychloroquine group and 3 in the placebo group; in

78 , there were 3 serious adverse events in the hydroxychloroquine group and 4 in the placebo group.

79 Viral load increased in the hydroxychloroquine group compared with placebo (0.61 log

80 ients reported influenza-like illness in the hydroxychloroquine group compared with the placebo group

81 All but 1 patient in the hydroxychloroquine group had detectable blood levels of

82 [95% CI, -1.6 to 3.3] in the clarithromycin-hydroxychloroquine group vs. the placebo group); the sco

83 (95% CI, 34.2 to 37.1) in the clarithromycin-hydroxychloroquine group, and 34.8 (95% CI, 33.4 to 36.2

84 doxycycline group, 96 in the clarithromycin-hydroxychloroquine group, and 98 in the placebo group).

85 group and 6.00 (2.52) to 5.94 (2.40) in the hydroxychloroquine group.

86 group and 6.53 (1.97) to 6.22 (1.87) in the hydroxychloroquine group.

87 group and 5.09 (3.06) to 4.59 (2.90) in the hydroxychloroquine group.

88 Hydroxychloroquine had no efficacy in patients with anti

89 The TLR7 to TLR9 blocker hydroxychloroquine has been in use in patients with lupu

90 stablished DMARDs, such as sulfasalazine and hydroxychloroquine, have also demonstrated efficacy when

91 Chloroquine (CQ) and hydroxychloroquine (HCQ) are used to treat auto-immune r

92 tudy the adherence of rheumatologists to the hydroxychloroquine (HCQ) dosing guidelines established b

93 Treatment with the antimalarial drug hydroxychloroquine (HCQ) has been associated with reduce

94 nt case-control study suggested a benefit of hydroxychloroquine (HCQ) in lowering the risk of cardiac

95 Hydroxychloroquine (HCQ) is often needed to manage disea

96 Prior research demonstrates that hydroxychloroquine (HCQ) lowers glycosylated hemoglobin

97 thalmology recommendations for screening for hydroxychloroquine (HCQ) retinopathy advise objective me

98 ations on screening for chloroquine (CQ) and hydroxychloroquine (HCQ) retinopathy are revised in ligh

99 lysosomotropic agent and autophagy inhibitor hydroxychloroquine (HCQ) synergizes with CCI-779 and led

100 Finally, we discuss hydroxychloroquine (HCQ) use by asymptomatic subjects wh

101 is showed that the combination of dnaJP1 and hydroxychloroquine (HCQ) was superior to the combination

102 In contrast, the autophagy inhibitors hydroxychloroquine (HCQ), 3-methyladenine (3-MA), and ba

103 Hydroxychloroquine (HCQ), a lysosomotropic amine, is an

104 re underway combining anticancer agents with hydroxychloroquine (HCQ), but concentrations of HCQ requ

105 investigated whether the antimalarial drug, hydroxychloroquine (HCQ), might affect this prothromboti

106 maximum tolerated dosage of MTX was reached, hydroxychloroquine [HCQ] was added) or parallel triple t

107 isk factors should help physicians prescribe hydroxychloroquine in a manner that will minimize the li

108 Hydroxychloroquine-induced pigmentation is not a rare ad

109 Hydroxychloroquine-induced pigmentation is not a rare ad

110 Our data support the hypothesis that hydroxychloroquine-induced pigmentation is secondary to

111 articipants into 2 groups: those affected by hydroxychloroquine-induced retinal toxicity and those un

112 Early detection of hydroxychloroquine-induced retinopathy is known to preve

113 e inner retina appears not to be involved in hydroxychloroquine-induced retinopathy to any clinically

114 g patients with rheumatoid arthritis, use of hydroxychloroquine is associated with a reduced risk of

115 herapy with methotrexate, sulfasalazine, and hydroxychloroquine is more effective than either methotr

116 Hydroxychloroquine is the most frequently prescribed imm

117 r vision and visual field in early stages of hydroxychloroquine maculopathy.

118 Two retrospective analyses suggest that hydroxychloroquine may prevent congenital heart block in

119 Treatment with a specific FXa inhibitor, hydroxychloroquine or fluvastatin significantly reduced

120 h IgG from normal human serum and fed either hydroxychloroquine or placebo.

121 rapy with the addition of sulfasalazine plus hydroxychloroquine (or etanercept, if necessary, after 6

122 atic drugs (methotrexate, sulfasalazine, and hydroxychloroquine) or etanercept plus methotrexate.

123 triple therapy (MTX plus sulfasalazine plus hydroxychloroquine), or step-up from MTX monotherapy to

124 Some patients treated with chloroquine, hydroxychloroquine, or colchicine develop autophagic vac

125 l course of doxycycline, clarithromycin plus hydroxychloroquine, or placebo.

126 mice, red blood cells, or P. falciparum over hydroxychloroquine- or primaquine-Sepharose.

127 t less likely to be receiving treatment with hydroxychloroquine (P = 0.003).

128 , vigabatrin (Sabril), tamoxifen (Nolvadex), hydroxychloroquine (Plaquenil)/chloroquine (Aralen), ami

129 xplain inhibition of TLR7 and 9 signaling by hydroxychloroquine (Plaquenil; Sanofi-Aventis, Bridgewat

130 TE) and a 12-month course of doxycycline and hydroxychloroquine prophylaxis in patients with signific

131 RDs without TNF inhibitors, methotrexate, or hydroxychloroquine (reference exposure).

132 ocal placoid pigment epitheliopathy (n = 1), hydroxychloroquine retinopathy (n = 1), and macular tela

133 Hydroxychloroquine retinopathy does not always develop i

134 Patients with hydroxychloroquine retinopathy involving the retinal pig

135 These data suggest that hydroxychloroquine retinopathy is more common than previ

136 The overall prevalence of hydroxychloroquine retinopathy was 7.5% but varied with

137 Clinical findings in patients with hydroxychloroquine retinopathy were monitored with repea

138 Of 201 total patients (18% Asian) with hydroxychloroquine retinopathy, 153 (76%) had typical pa

139 res and long-term follow-up of patients with hydroxychloroquine retinopathy, making it difficult to s

140 sted to recognize pericentral and parafoveal hydroxychloroquine retinopathy.

141 hy, early retinopathy, or moderate or severe hydroxychloroquine retinopathy.

142 -derived collagen, and a large case study of hydroxychloroquine retinotoxicity.

143 New therapeutic agents such as statins, hydroxychloroquine, rituximab, complement inhibitors, an

144 s, we discuss the candidate therapies, i.e., hydroxychloroquine, rituximab, eculizumab, sirolimus, an

145 Of patients presenting for hydroxychloroquine screening, 54.8% of patients received

146 red or white fields should be acceptable for hydroxychloroquine screening, as long as the clinician i

147 With white 10-2 visual field hydroxychloroquine screening, the use of pattern deviati

148 However, drugs such as hydroxychloroquine seem to modify coronary heart disease

149 Hydroxychloroquine significantly diminished both thrombu

150 Also, the triple combination of hydroxychloroquine, sulfasalazine, and methotrexate is v

151 y, 3) cyclosporine + MTX, 4) triple therapy (hydroxychloroquine, sulfasalazine, and MTX), 5) continua

152 t resulted in treatment with > or = 1 DMARD (hydroxychloroquine, sulfasalazine, auranofin, intramuscu

153 binations of methotrexate plus cyclosporine, hydroxychloroquine, sulfasalazine, leflunomide, etanerce

154 Hydroxychloroquine sulfate is widely used for the long-t

155 Hydroxychloroquine sulfate retinopathy can progress afte

156 endations, long-term users of chloroquine or hydroxychloroquine sulfate should undergo regular visits

157 inopathy is a known risk of long-term use of hydroxychloroquine sulfate.

158 Decline in CD4 cell count was greater in the hydroxychloroquine than placebo group (-85 cells/muL vs

159 d future clinical trials involving high-dose hydroxychloroquine to improve safety monitoring and pres

160 brane carries a positive prognostic value in hydroxychloroquine toxic effects because it may be assoc

161 Early recognition of hydroxychloroquine toxic effects before any fundus chang

162 Relative foveal resistance in hydroxychloroquine toxic effects was supported by this c

163 Given the infrequent occurrence of hydroxychloroquine toxic effects, few data are available

164 itivity and specificity for the detection of hydroxychloroquine toxicity as identified by mfERG, and

165 New hydroxychloroquine toxicity was found in 2 of 183 return

166 ily dosing is a cost-effective way to reduce hydroxychloroquine toxicity, but height, weight, and dai

167 e an ACR50 response at 2 years compared with hydroxychloroquine-treated patients (60% compared with 3

168 Mean age and duration of hydroxychloroquine treatment did not differ statisticall

169 ean age, 55.7+/-10.4 years; mean duration of hydroxychloroquine treatment, 15.0+/-7.5 years) were div

170 5% CI 1-1.38) were associated with ROM loss, hydroxychloroquine use (OR 11.2, 95% CI 3.7-33) and calc

171 ificantly reduced with increased duration of hydroxychloroquine use (P < .001 for trend); among those

172 To determine the association between hydroxychloroquine use and the incidence of self-reporte

173 Hydroxychloroquine use for at least 5 years.

174 Patients' amount of chloroquine or hydroxychloroquine use in the 5 years since the initial

175 nts, each additional month of chloroquine or hydroxychloroquine use was associated with a 2.0% increa

176 Hydroxychloroquine use was not predictive.

177 .1%) had at least 1 record of chloroquine or hydroxychloroquine use, and 1409 (7.8%) had used chloroq

178 focal parafoveal thinning, a toxic effect of hydroxychloroquine use.

179 Hydroxychloroquine used for treating systemic lupus eryt

180 tinal thickness between short- and long-term hydroxychloroquine users (n = 27) in different retinal r

181 Among chloroquine or hydroxychloroquine users and those at high risk for toxi

182 e was seen in the SD-OCT images of long-term hydroxychloroquine users until the actual appearance of

183 its in >/=3 of 5 years) among chloroquine or hydroxychloroquine users, including those at highest ris

184 cident diabetes among patients who had taken hydroxychloroquine was 0.62 (95% confidence interval, 0.

185 8 (35.7%), the dose was reduced, in 2 (7.1%) hydroxychloroquine was stopped, but in 16 (57.1%) no act

186 Hydroxychloroquine was the most commonly cited medicatio

187 evels, use of glucocorticoids, and nonuse of hydroxychloroquine were all significantly associated wit

188 eatment of mice with the autophagy inhibitor hydroxychloroquine, which is currently being used in sev

189 We studied retrospectively 13 patients using hydroxychloroquine who had undergone both red (FASTPAC)

190 ew was performed to identify patients taking hydroxychloroquine who were screened for toxic effects f

191 uine and by 171 patients who had never taken hydroxychloroquine, with incidence rates of 5.2 per 1000

192 bromocriptine, immunoadsorption columns, and hydroxychloroquine withdrawal.

193 ut TNF inhibitors or hydroxychloroquine; (3) hydroxychloroquine without TNF inhibitors or methotrexat